First-line anti-tuberculosis drug resistance patterns and trends at the national TB referral center in Iran-eight years of surveillance

International Journal of Infectious Diseases

Volumn 13, Issue 5, 2009, Pages

  Shamaei, Masoud ^a   Marjani, Majid ^a   Chitsaz, Ehsan ^a   Kazempour, Mehdi ^a   Esmaeili, Mehdi ^a   Farnia, Parisa ^a   Tabarsi, Payam ^a   Amiri, Majid V ^a   Mirsaeidi, Mehdi ^a   Mansouri, Davood ^a   Masjedi, Mohammad R ^a   Velayati, Ali A ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Drug resistance; Iran; Trends; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; RIFAMPICIN; STREPTOMYCIN;

ADOLESCENT; ADULT; AFGHANISTAN; AGE DISTRIBUTION; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; CROSS-SECTIONAL STUDY; DRUG SENSITIVITY; DRUG SURVEILLANCE PROGRAM; ETHNICITY; FEMALE; HEALTH CENTER; HEALTH PROGRAM; HUMAN; IRAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTIDRUG RESISTANT TUBERCULOSIS; PATIENT REFERRAL; RACE DIFFERENCE; RETREATMENT; RETROSPECTIVE STUDY; SEX DIFFERENCE; TUBERCULOSIS; TUBERCULOSIS CONTROL;

ADOLESCENT; AGED; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; IRAN; ISONIAZID; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; NATIONAL HEALTH PROGRAMS; POPULATION SURVEILLANCE; REFERRAL AND CONSULTATION; RIFAMPIN; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 69249245345     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2008.11.027     Document Type: Article

References (31)

1. Antonucci G., Girardi F., Raviglione M.C., and Ippolito G. Risk factors for tuberculosis in HIV-infected persons. A prospective cohort study. JAMA 274 (1995) 143-148
2. Prammananan T., Arjratanakool W., Chaiprasert A., Tingtoy N., and Leechawengwong M. Second-line drug susceptibilities of Thai multidrug-resistant Mycobacterium tuberculosis isolates. Int J Tuberc Lung Dis 9 (2005) 216-219
3. Brudney K., and Dobkin J. Resurgent tuberculosis in New York City, human immunodeficiency virus, homelessness, and the decline of tuberculosis control programs. Am Rev Respir Dis 144 (1991) 745-749
4. World Health Organization/International Union Against Tuberculosis and Lung Disease (WHO/IUATLD). Anti-tuberculosis drug resistance in the world. The WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance 1994-1997. WHO/TB/97.229. Geneva: WHO/IUATLD; 1997.
5. Mitchison D.A., and Nunn A.J. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 133 (1986) 423-443
6. Valenzuela P., Valenzuela M.T., and Ponce J. Response to short-course chemotherapy of patients with initial resistance to antituberculosis drugs. Bull Pan Am Health Organ 22 (1988) 175-183
7. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2006.361. Geneva: WHO; 2006.
8. Iseman M.D., and Madsen L.A. Drug-resistant tuberculosis. Clin Chest Med 10 (1989) 341-353
9. Goble M. Drug-resistant tuberculosis. Semin Respir Infect 1 (1986) 220-229
10. Nathanson E., Lambregts-van Weezenbeek C., Rich M.L., Gupta R., Bayona J., Blöndal K., et al. Multidrug-resistant tuberculosis management in resource-limited settings. Emerg Infect Dis 12 (2006) 1389-1397
11. World Health Organization. Addressing the threat of tuberculosis caused by extensively drug-resistant Mycobacterium tuberculosis. Wkly Epidemiol Rec 81 (2006) 386-390
12. World Health Organization. Extensively drug-resistant tuberculosis (XDR TB): recommendations for prevention and control. Wkly Epidemiol Rec 81 (2006) 430-432
13. Raviglione M.C., Dye C., Schmidt S., and Kochi A. Assessment of worldwide tuberculosis control. Lancet 350 (1997) 624-629
14. Mansouri S.D., Arami S., Mirabolhasani Z., Farnia P., and Velayati A.A. Pattern of drug resistance among newly diagnosed and old cases of pulmonary tuberculosis in NRITLD. Arch Iranian Med 6 (2003) 255-260
15. Mirsaeidi M.S., Tabarsi P., Farnia P., Ebrahimi G., Morris M.W., Masjedi M.R., et al. Trends of drug resistant Mycobacterium tuberculosis in a tertiary tuberculosis center in Iran. Saudi Med J 28 (2007) 544-550
16. World Health Organization, Regional Office for the Western Pacific. Guidelines for the control of tuberculosis through DOTS strategy in Pacific Island Countries; 1999. Available at: http://www.wpro.who.int/NR/rdonlyres/373982C6-3485-4AA8-896F-10C1907D366 E/0/tbguide.pdf (accessed December 2008).
17. Mirsaeidi S.M., Tabarsi P., Khoshnood K., Pooramiri M.V., Rowhani-Rahbar A., Mansouri S.D., et al. Treatment of multiple drug-resistant tuberculosis (MDR-TB) in Iran. Int J Infect Dis 9 (2005) 317-322
18. World Health Organization. Standardization of methods for conducting microbic sensitivity tests. World Health Organ Tech Rep Ser 210 (1961) 3-24
19. Canetti G., Fox W., Khomenko A., Mahler H.T., Menon N.K., Mitchison D.A., et al. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Organ 41 (1969) 21-43
20. Zignol M., Hosseini M.S., Wright A., Weezenbeek C.L., Nunn P., Watt C.J., et al. Global incidence of multidrug-resistant tuberculosis. J Infect Dis 194 (2006) 479-485
21. Aziz M.A., Wright A., Laszlo A., De Muynck A., Portaels F., Van Deun A., et al. Epidemiology of antituberculosis drug resistance (the Global Project on Antituberculosis Drug Resistance Surveillance): an updated analysis. Lancet 368 (2006) 2142-2154
22. Pablos-Méndez A., Raviglione M.C., Laszlo A., Binkin N., Rieder H.L., Bustreo F., et al. Global surveillance for antituberculosis drug resistance, 1994-1997. N Engl J Med 338 (1998) 1641-1649
23. Al-Tawfiq J.A., Al-Muraikhy A.A., and Abed M.S. Susceptibility pattern and epidemiology of Mycobacterium tuberculosis in a Saudi Arabian hospital: a 15-year study from 1989 to 2003. Chest 128 (2005) 3229-3232
24. Ormerod L.P. Multidrug-resistant tuberculosis (MDR-TB): epidemiology, prevention and treatment. Br Med Bull 73-74 (2005) 17-24
25. Irish C., Herbert J., Bennett D., Gilham C., Drobniewski F., Williams R., et al. Database study of antibiotic resistant tuberculosis in the United Kingdom, 1994-6. BMJ 318 (1999) 497-498
26. Djuretic T., Herbert J., Drobniewski F., Yates M., Smith E.G., Magee J.G., et al. Antibiotic resistant tuberculosis in the United Kingdom: 1993-1999. Thorax 57 (2002) 477-482
27. Frieden T.R., Sterling T., Pablos-Mendez A., Kilburn J.O., Cauthen G.M., Dooley S.W., et al. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 329 (1993) 148
28. UN Press Release SC/7751. Unstable, insufficient security in Afghanistan casts long shadow over peace process, special representative tells security council; 2003. Available at: http://www.un.org/News/Press/docs/2003/sc7751.doc.htm (accessed December 2008).
29. Caminero J.A. Treatment of multidrug-resistant tuberculosis: evidence and controversies. Int J Tuberc Lung Dis 10 (2006) 829-837
30. Bloomberg B., Spinaci S., Fourie B., and Laing R. The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis. Bull World Health Organ 79 (2001) 1-15
31. Mitchison D.A. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int J Tuberc Lung Dis 2 (1998) 10-15